Evidence map›Paper›PMID 30188015›Full record

ArticleCancer medicine2018

Trends in treatment and survival of patients with nonresected, nonmetastatic pancreatic cancer: A population-based study.

Lydia G M van der Geest, Casper H J van Eijck, Bas Groot Koerkamp, Valery E P P Lemmens, Olivier R Busch, Pauline A J Vissers, Johanna W Wilmink, Marc G Besselink, Dutch Pancreatic Cancer Group

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.4field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 31 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Lydia G M van der GeestDepartment of Research, Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, The Netherlands.ORCID 0000-0003-1637-5520
Casper H J van EijckDepartment of Surgery, Erasmus Medical Center, Rotterdam, The Netherlands.
Bas Groot KoerkampDepartment of Surgery, Erasmus Medical Center, Rotterdam, The Netherlands.
Valery E P P LemmensDepartment of Research, Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, The Netherlands.
Olivier R BuschDepartment of Surgery, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
Pauline A J VissersDepartment of Research, Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, The Netherlands.
Johanna W WilminkDepartment of Medical Oncology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
Marc G BesselinkDepartment of Surgery, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
Dutch Pancreatic Cancer Group
Amsterdam UMC Location University of Amsterdam · NLErasmus MC · NLNetherlands Comprehensive Cancer Organisation · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundNonresected, nonmetastatic (NR-M0) pancreatic cancer involves both locally advanced pancreatic cancer and patients who did not undergo resection due to poor health status or patient preference. This study investigates nationwide trends of characteristics, treatment, and survival of patients with NR-M0 pancreatic cancer.

methodsFrom the Netherlands Cancer Registry, all patients diagnosed with pancreatic cancer between 2006 and 2014 were selected. Chemotherapy and overall survival (OS) of NR-M0 patients were evaluated for 3-year time periods and 2 age groups using chi-square tests for trend and Cox proportional hazard regression analysis.

resultsOf 18 234 patients, 33% had NR-M0 pancreatic cancer, which decreased over time (in consecutive 3-year periods: 38%-33%-28%, P < 0.001). Of 5964 NR-M0 patients, 52% was over 75 years of age, 16% received chemotherapy, and median OS was 5.1 months. Chemotherapy use increased over time in younger patients (<75 years: from 23 to 36%, P-trend < 0.001, ≥75 years: 3% to 4%, P-trend = 0.053). In multivariable survival analysis, elderly age, low SES, nonconfirmed cancer, stage II-III disease, and earlier years of diagnosis were independently associated with a worse OS. Age of patients who received chemotherapy increased over time (median 62-66 years) and median OS was 10.4 months without significant differences between time periods (P = 0.177) or age groups (P = 0.207).

conclusionsOverall survival of NR-M0 pancreatic cancer remains poor which is partly related to advanced age of many patients. Despite an increase, chemotherapy is infrequently used. Future research should investigate to what extent the more widespread use of chemotherapy could improve survival in relation to age-related morbidity.

Indexed as

AgedAged, 80 and overAge FactorsDrug TherapyFemaleHumansMaleNeoplasm StagingNetherlandsPancreatic NeoplasmsRegistriesSurvival Analysischemotherapynonresectedpancreatic adenocarcinomasurvival

Identifiers

PMID30188015
PMCPMC6198237
OpenAlexW2892033277

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.